Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ICLE 2022 | Optimizing CAR therapies with DART-AAV vector technology

Alexander Michels • 1 Apr 2022
ICLE 2022
General CAR-T

Alexander Michels, Paul-Ehrlich-Institut, Langen, Germany, discusses the role of DARPin-targeted adeno-associated virus (DART-AAV) vectors in the development of chimeric antigen receptor (CAR)-T cell therapies. Standard AAV vectors are unable to carry out selective transduction, and a majority of studies in the CAR therapies utilize synthetic and lentiviral vectors. The advent of DART-AAV vectors enables directed evolution of the vectors themselves and are flexible in targeting various cell types including CD8 cells. This interview took place at the International Conference on Lymphocyte Engineering (ICLE) 2022.

More from Alexander Michels

Comparing mouse models for the study of immunotherapies
1:21
Comparing mouse models for the study of immunotherapies
Alexander Michels • 1 Apr 2022
Testing viral vectors for CAR therapies with in vivo models
1:57
Testing viral vectors for CAR therapies with in vivo models
Alexander Michels • 1 Apr 2022

Related Videos

The ethical challenges of AI in hematology: patient communication, trust and regulation
3:12
The ethical challenges of AI in hematology: patient communication, trust and regulation
Adrián Mosquera Orgueira • 24 Sep 2026
The future of AI in hematology: personalized medicine, opportunities and risks
2:30
The future of AI in hematology: personalized medicine, opportunities and risks
Adrián Mosquera Orgueira • 24 Sep 2026
The multi-system impacts of CHIP and its link to subspecialties within internal medicine
5:18
The multi-system impacts of CHIP and its link to subspecialties within internal medicine
Shyam Patel • 13 Oct 2026
The scientific and clinical implications of therapy-related CHIP in oncology
2:43
The scientific and clinical implications of therapy-related CHIP in oncology
Shyam Patel • 13 Oct 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals